

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

April 2014

Volume 17, Number 4, Supplement 1

For Health Professionals Who Care For Cancer Patients

SUPPLEMENT

NEW PROGRAMS

The Provincial Systemic Therapy Program has approved the following program effective immediately:


Breast:

Oncotype DX® Breast Cancer Assay in Hormone Receptor-Positive and Node-Negative Early Breast Cancer

The BCCA Breast Tumour Group has implemented the Oncotype DX® assay as a treatment decision-making tool to guide oncologists in determining whether a patient would benefit from adjuvant chemotherapy. This assay uses molecular prognostic profiling to produce a validated 21-gene recurrence score, which estimates the 10-year breast cancer recurrence risk in patients with hormone receptor-positive, node-negative breast cancer who are treated with 5 years of tamoxifen. [Paik S et al. NEJM 2004;351: 2817-2826]

The recurrence score also estimates the magnitude of benefit a patient may receive from adjuvant chemotherapy. Ultimately, this assay guides oncologists in identifying patients who may obtain a significant benefit from adjuvant chemotherapy, while sparing those who may obtain minimal clinical benefit from the short- and long-term toxicities of chemotherapy.

Patients are eligible to receive BCCA-funded Oncotype DX® testing if the following eligibility criteria are met:



SUPPLEMENT

Detailed information about the Oncotype DX® testing process and the following required documents can be found on the BCCA website at: <http://www.bccancer.bc.ca/HPI/labservices/Oncotype+DX+testing.htm>.

- Patient consent form
- Genomic Health Incorporated (GHI) requisition form
- Ordering process flow sheet

Oncotype DX® testing is performed at Genomic Health Incorporated (GHI) in California, USA. Please adhere to the specified processes on the website as significant privacy issues are associated with sending specimens to the US.

A Compassionate Access Program (CAP) approval must be granted prior to proceeding with Oncotype DX® testing. Clinicians must submit a CAP application, and fax the signed patient consent form and the GHI requisition form to the CAP office (fax no. 604-708-2026) for approval. The CAP program will requisition the test directly with GHI, and GHI will then connect with the appropriate laboratory to obtain the required tissue specimens. Testing not requisitioned through the CAP program will not be funded by the BCCA. For CAP requests that have been denied, clinicians will be notified and the patient consent form will be shredded for confidentiality purposes. Appeals can be done through the normal CAP appeal process as outlined in the [BCCA Compassionate Access Program \(CAP\) Policy \(III-45\)](#).

Status updates during the testing process can be accessed on the GHI Patient Portal at: <https://online.genomichealth.com/Login.aspx>. It is important that a secure password is used for this website to protect patient information. BCCA recommends that the password contains at least 15 characters and that clinicians always sign off the website before walking away from the computer terminal. Finally, please be reminded that patient information should *never* be emailed to the company as this will compromise patient confidentiality. All information regarding the status of the testing can be obtained from the GHI Patient Portal.

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	
	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
CON Pharmacy Educators	http://www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 673028		sally.waignein@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD

Beth Morrison, MLS
 Susan Walisser, BSc (Pharm)
 Ava Hatcher, RN